DASA-58 is primarily used in research settings as a selective antagonist for dopamine D3 receptors. It helps in studying the role of D3 receptors in neurological pathways, particularly in conditions related to addiction, schizophrenia, and Parkinson’s disease. Its high selectivity allows scientists to isolate D3 receptor activity without significantly affecting D2 receptors, making it a valuable tool in neuropharmacology. It is also used in behavioral studies to assess the impact of D3 receptor modulation on reward-seeking and motor control. Due to its research-focused profile, it is not used clinically but supports the development of new therapeutic agents targeting dopamine signaling.